Summary
Uterine leiomyosarcoma (ULMS) develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine ULMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known.
Importantly, a diagnostic-biomarker which distinguishes malignant ULMS from benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine ULMS, to establish a treatment method. Proteasome low-molecular mass polypeptide 2(LMP2)/β1i-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. We found LMP2/β1i expression to be absent in human LMS, but present in human LMA. Therefore, defective-LMP2/β1i expression may be one of the risk factors for ULMS. LMP2/β1i is a potential diagnostic-biomarker for uterine ULMS, and may be a targeted-molecule for a new therapeutic approach. (153 words) The uterus, the organ in which the embryo grows, is composed of three layers, the uterine endometrium which serves as a bed for the embryo; the myometrium of the wall which protects the embryo; and a serous membrane enveloping the uterus. In general, the term uterine tumor refers to an epithelial malignant tumor of the uterus, which is roughly classified as a tumor of the uterine cervix or the uterine body. Because of the prevalence of screening, uterine cervix cancer is decreasing in incidence, and usually detected at a very early stage. In contrast, cancer of the uterine body is increasing in incidence, and rarely detected at the initial stages. While most tumors of the uterine body are adenocarcinomas (derived from the subintimal gland), tumors of the uterine cervix are classified into squamous cancer and adenocarcinoma. Smooth muscle tumors (SMTs) which develop in the myometrium have been traditionally divided into benign LMA and malignant ULMS based on cytological atypia, mitotic activity and other criteria. Uterine LMS is relatively rare, having an estimated annual incidence of 0.64 per 100,000 women 1 . ULMS accounts for 2% to 5% of tumors of the uterine body and develops more often in the muscle layer of the uterine body than in the uterine cervix. As uterine ULMS is resistant to chemotherapy and radiotherapy, surgical intervention is virtually the only means of treatment [2] [3] [4] 8, 9 (NOTE 1).
The non-standard subtypes of uterine SMTs such as the epithelioid and myxoid types are classified in a different way using these features, so the establishment of a diagnostic method for the identification of non-standard smooth muscle differentiation is important 8, 9 .
High estrogen levels are considered to significantly influence the development of tumors in the uterine body [10] [11] [12] Cytoplasmic proteins are mostly degraded by a protease complex, which has many substrates consisting of twenty-eight 20 to 30-kDa subunits, referred to as the 20S proteasome, and it is located in the nucleus and the cytoplasm 13, 14 . The proteasomal degradation is essential for many cellular processes, including the cell cycle, the regulation of gene expression and immunological function 15 . Interferon-γ (IFN-γ) induces the expression of large numbers of responsive genes, proteasome subunits, i.e., LMP2/β1i, LMP7/β5i, and LMP10/β2i 16 . The individual expression of the low molecular weight protein (LMP)2, LMP7, and LMP10(MECL-1) subunits is believed to contribute to the initiation and development of disorders. A recent study revealed a unique role for LMP7 in controlling pathogenic immune responses and provided a therapeutic rationale for targeting LMP7 in autoimmune disorders, especially rheumatoid arthritis 17 . Recent reports demonstrate LMP2/β1i, as obligatory for tumor surveillance and demonstrate a tissue-specific role for LMP2/β1i in protection from spontaneous uterus neoplasms 18, 19 .
Homozygous mice deficient in LMP2/β1i show tissue-and substrate-dependent abnormalities in the biological functions of the proteasome 18, 20 . ULMS reportedly occurred in Nature
female LMP2/β1i-null mice at age 6 months or older, and the incidence at 14 months of age was about 40% 19, 20 . The curve indicating the incidence in mice is similar to that indicating the incidence of human ULMS, which occurs after menopause. Histological studies of LMP2/β1i-null uterine tumors have revealed characteristic abnormalities of ULMS 19 . The tumors lacked lymphoid infiltrates, a sign of immune recognition, and consisted of uniform elongated myometrium cells arranged into bundles. The nuclei of the tumor cells varied in size and shape, furthermore, mitosis was frequent. In contrast, the myometrium cells of C57BL/6 mice were normal in appearance 19 . Whereas relatively few Ki-67-positive cells, the proliferating cells of solid tumors, were observed in the basal cell layer of the normal myometrium, most of the basal cells vividly expressed Ki-67 in LMP2/β1i-null mice 19 . This immunological staining indicates abnormal proliferation of the LMP2/β1i-lacking cells in the basal layer. LMP2/β1i-null mice that have developed uterine ULMS undergo considerable weight loss, and then die by 14 months of age. The LMP2/β1i-null mice also exhibit skeletal muscle metastasis from ULMS 21 . Therefore it is likely that LMP2/β1i-null mice with uterine LMS die as a result of the tumor mass and metastasis. In general, it is not easy to distinguish uterine LMA from ULMS, however, in mice, because of such characteristic pathological findings, significant weight loss, and skeletal muscle metastasis, a tumor that develops in the uterus of an LMP2/β1i-null mouse can be considered malignant, i.e., a ULMS 19, 20 .
Furthermore, IHC revealed a serious loss in the ability to induce LMP2/β1i expression in human ULMS tissue in comparison with LMA or normal myometrium located in the same section 22, 23 . Of the 54 cases we examined with ULMS, 46 were negative for LMP2/β1i expression, 4 were focally positive, and 2 were partially positive 23 . Two ULMS cases were stained for LMP2/β1i. LMP2/β1i levels were also evaluated in skeletal muscle and rectum metastases from individual ULMS patients 23 . Pathological examination of surgical samples showed the presence of a mass measuring 3 cm in its largest diameter in the lumbar quadrate muscle without a fibrous capsule. All lymph nodes were negative for ULMS metastases, and IHC analyses showed positivity for Ki-67 and negativity for LMP2/β1i 23 . Histological findings were consistent with metastatic LMS for the skeletal muscle and rectum lesions 23 . In western blotting and RT-PCR experiments, LMP2/β1i was expressed in normal myometrium, but not in human ULMS, both strongly supportive of the IHC findings 22, 23 . Although we has previously demonstrated that the abnormal expression of the ovarian steroid receptors, TP53
and Ki-67 and mutations of TP53 were frequently associated with ULMS, defective LMP2
expression appears to be more characteristic of ULMS than these factors [22] [23] [24] .
In the case of gynecological cancers, such as breast cancer, a female hormonal imbalance is often a risk factor for developing tumors [10] [11] [12] . As in the case of uterine LMA, however, a correlation between the development of ULMS, the female hormone, and hormone receptors has yet to be elucidated. A recent report showed the expression of Lmp2/β1i mRNA and protein in luminal and glandular epitheliua, placenta villi, trophoblastic shells, and arterial endothelial cells [25] [26] [27] . These results implicate LMP2/β1i in the invasion of placental villi, degradation of the extracellular matrix, immune tolerance, glandular secretion, and angiogenesi -27 . The present study should help to elucidate the regulatory role of LMP2/β1i in the implantation of embryos [25] [26] [27] . Further experiments are al so required to elucidate the molecular mechanism of ULMS tumorigenesis involved biological significance of LMP2.
The LMP2/β1i -null mouse was the first animal model of spontaneous ULMS to be Table 1 .
Clarification of the correlation between these factors and the development of ULMS and the identification of specific risk factors may lead to the development of new treatments for the disease. ULMS is refractory to chemotherapy and has a poor prognosis. The molecular biological and cytological information obtained from LMP2-null mice will contribute remarkably to the development of preventive methods, a potential diagnostic-biomarker, and new therapeutic approaches against ULMS.
(NOTE 1) The typical gross appearance is a large (>10cm), poorly circumscribed mass with a soft, fleshy consistency and a variegated cut surface that is grey-yellow to pink, with foci of hemorrhage and necrosis 8, 9 . The histologic classification of uterine sarcomas is based upon homology to normal cell types and include ULMS (analogous to myometrium), stromal sarcoma (analogous to endometrial stroma), and other heterologous cell types (i.e., osteosarcoma, liposarcoma). Microscopically, most ULMS are overtly malignant, with hypercellularity, coagulative tumor cell necrosis, abundant mitoses (>10 to 20 mitotic figures 6 6 (mf) per 10 high power fields (hpf)), atypical mitoses, cytologic atypia, and infiltrative borders. Mitotic rate is the most important determinant of malignancy, but is modified by the presence of necrosis and cytologic atypia. The diagnosis of ULMS may be made in the presence of tumor necrosis and any mitoses. In the absence of tumor necrosis, the diagnosis can be made with moderate to severe cytologic atypia and a mitotic index greater than 10mf/10hpf. Without tumor necrosis and significant atypia, a high mitotic index is compatible with a benign clinical course, however, data is limited 8, 9 
